Saliva point-of-care testing for suboptimal levofloxacin and linezolid exposure in multidrug-resistant tuberculosis
Abstract
Graphical abstract Overview of the study. Background Therapeutic drug monitoring may optimise treatment outcomes in patients with multidrug-resistant tuberculosis, yet current methods are invasive and resource intensive. This study evaluated the feasibility of using saliva point-of-care testing to screen for suboptimal exposure to levofloxacin and linezolid. Methods We conducted a community-based cross-sectional study in Vietnam (2021–2023). Drug concentrations were measured in paired plasma and saliva samples at 0, 2 and 5 h post-dose, using a point-of-care test (NanoPhotometer NP80) in comparison with liquid chromatography-mass spectrometry. Drug exposure (area under the drug concentration–time curve from 0 to 24 h (AUC0–24)) was calculated using a Bayesian population pharmacokinetic approach (Edsim++). Therapeutic targets were defined as a free AUC0–24 to minimum inhibitory concentration ratio of 160 for levofloxacin and 125 for linezolid. Receiver operating characteristic curve analyses were conducted to determine optimal saliva thresholds for predicting subtherapeutic or supratherapeutic plasma exposure. Results A saliva exposure threshold of 70.3 mg·h·L−1 accurately identified 16 out of 19 patients with subtherapeutic levofloxacin plasma exposure (sensitivity 84%, specificity 78%; n=60). For linezolid (n=17), saliva testing correctly identified the only patient with subtherapeutic exposure and the only patient with supratherapeutic exposure. However, no saliva exposure…
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.